Healthcare AI teams are using synthetic data to work around scarce, slow-to-access patient records. The upside is speed; the downside is that bias, safety, and integrity issues can ship faster too unless teams validate against real-world data.
Healthcare leaders use synthetic data to address patient-record scarcity for AI builds
Healthcare technology leaders are increasingly adopting synthetic data to compensate for limited usable patient records needed to train and test AI-driven clinical decision support systems. The source describes a scenario where teams have only 500 usable patient records, while access to real datasets is constrained by lengthy compliance reviews and the operational risk of breaches.
The appeal is straightforward: synthetic data can be generated and shared without direct patient identifiers, potentially reducing dataset access and iteration cycles from months to minutes. But the same shortcut can introduce failure modes—especially if synthetic data is treated as a drop-in replacement for real-world distributions without hard validation and monitoring.
- Speed is real, but so is model risk: synthetic datasets can accelerate prototyping and internal evaluation, but teams still need evidence that performance and safety characteristics hold on real-world data.
- Bias can be amplified, not removed: if the source data is skewed, synthetic generation may replicate or intensify those skews—creating clinically harmful recommendations downstream.
- Privacy posture shifts, not disappears: “no identifiers” is not the same as “no risk.” Data and privacy teams still need controls, documentation, and review gates before synthetic data is used for clinical-facing systems.
In the example cited, teams had only 500 usable patient records, while breach costs were cited as averaging $11 million—pressure that pushes organizations toward synthetic alternatives.